# Nasdaq's Wild Ride: Splits, Stocks, and Surprises!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-07-30T14:00:00.258Z
Source: https://newsyai.com/edition/a243123a-236c-4404-b145-32202061bae9
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

**Nasdaq’s Reverse-Split Circus: Hong Kong Interiors, Biotech Moonshots & Mystery 150x Splits – July 30, 2026 Edition!**

Futures mixed (Dow napping, Nasdaq huffing AI/chip fumes, crude oil still flexing). Yesterday’s gold/mining/SaaS split fiesta is yesterday’s news. The Nasdaq MVLS $5M noose keeps tightening—no extra chances for repeat offenders. Fresh meat today: three volatility junkies where bulls sniff compliance pops and sector fantasies while bears smell dilution graves and execution flops.[[1]](https://finance.yahoo.com/calendar/splits/)

### 1) NIMU (Non Invasive something-or-other): “1-for-150 Mystery Split vs. Whatever-the-Hell-They-Do & Dilution Apocalypse”

**Why it’s loud**  
Insane 1-for-150 reverse split hitting today for compliance. Tiny float, microcap vibes, and a name that screams “we might be in medtech… or maybe not.” Bulls chase any post-split bounce or vague sector tailwind; bears hammer the ridiculous ratio as a desperate scream for capital and probable graveyard residency.[[2]](https://www.stocktitan.net/news/stock-splits.html)

**Bull case (compliance rocket + mystery boner)**  
150x ratio + volume spike + any positive whisper = potential rip. Ride the “whatever it is” fantasy, degens—shrunken float turns noise into rocket fuel!

**Bear case (dilution gangbang & split limp encore)**  
150x desperation? That’s not a split, that’s a funeral. Endless raises, zero visibility, brutal microcap reality = sub-penny cemetery. Short the fade before the next offering tsunami!

**My take, first principles (real signal vs. listing cancer)**  
Zero operational clarity + extreme ratio + stricter Nasdaq MVLS scrutiny + microcap chaos = unsustainable trap. Short-term hype lottery at best. Scalp the spunk? **$0.05–1.50** range, **$0.40C** mystery pump—**P$0.04** dilution fade.

### 2) OFAL (OFA Group): “1-for-10 Hong Kong Interiors Play vs. Bid-Price Limbo & Dilution Risks”

**Why it’s loud**  
1-for-10 reverse split effective tomorrow (July 31) amid Nasdaq compliance push. Hong Kong-based interior design, fit-out, and project management services for commercial/residential buildings. Bulls eye any China/HK recovery or contract wins with the shrunken float; bears hammer thin margins, governance flags, and “Asian microcap” execution flops.[[3]](https://www.nasdaqtrader.com/TraderNews.aspx?id=eca2026-534)

**Bull case (compliance stiffy + design erection)**  
Solid ratio + volume pop + any HK real estate tailwind = $1–4+ rip. Ride the interiors fantasy, apes!

**Bear case (dilution gangbang & split limp encore)**  
10x desperation screams capital hunger, brutal sector competition, repeated raises = sub-$0.05 cemetery. Short the fade before the next offering tsunami!

**My take, first principles (real services signal vs. listing cancer)**  
Genuine niche services narrative offers short-term hype juice, but HK/China macro headwinds, dilution history, stricter Nasdaq MVLS scrutiny, and microcap volatility scream trap. Real operational play with lottery vibes. Scalp it? **$0.08–2.10** range, **$0.45C** design pump—**P$0.06** dilution fade.

### 3) CLDI (Calidi Biotherapeutics): “1-for-16 Biotech Virotherapy Dream vs. Cash Burn & Compliance Limbo”

**Why it’s loud**  
1-for-16 reverse split effective tomorrow (July 31). Clinical-stage biotech developing targeted virotherapies/genetic medicines. Bulls drool over any trial data, partnership, or oncology tailwind with the post-split float; bears pound ongoing losses, cash burn, and “biotech microcap” volatility.[[4]](https://finance.yahoo.com/quote/CLDI/)

**Bull case (compliance rocket + science boner)**  
Aggressive ratio + volume spike + any clinical catalyst = $1–5+ rip. Ride the virotherapy fantasy, degens!

**Bear case (dilution gangbang & split limp encore)**  
16x desperation screams capital needs, brutal biotech competition, repeated raises = sub-$0.05 graveyard. Short the fade before the next offering tsunami!

**My take, first principles (real science signal vs. listing cancer)**  
Genuine biotech pipeline offers short-term narrative juice, but cash burn reality, dilution overhang, new MVLS rules, and microcap chaos scream unsustainable trap. Real clinical lottery with moonshot potential. Scalp the spunk? **$0.07–1.90** range, **$0.42C** science pump—**P$0.05** dilution fade.

**Tape-Side Tactics (NIMU Mystery Mayhem, OFAL Interiors Grind & CLDI Biotech Boner – July 30 Edition)**  
- **NIMU**: **$0.05–1.50** stiffy; **$0.40C** mystery pump, **P$0.04** fade.  
- **OFAL**: **$0.08–2.10** stiffy; **$0.45C** design pump, **P$0.06** fade.  
- **CLDI**: **$0.07–1.90** stiffy; **$0.42C** science pump, **P$0.05** fade.  

New MVLS rules still tightening the noose amid crude cock-up and micro-madness. Balls-deep DYOR, NFA, degens duck the dilutions!

**Sources** (for tracking every claim above):  
- Reverse splits & reactions: Yahoo Finance Stock Splits Calendar, StockTitan, Nasdaq Trader alerts (July 30, 2026 data).  
- Company announcements & details: GlobeNewswire, company filings via Yahoo Finance/OTC Markets.  
- Nasdaq reverse-split rule changes & MVLS: SEC filings, Nasdaq Listing Rules (2026 updates).  
- Broader microcap/premarket context & volatility: Yahoo Finance, recent market data.
